Quarterly ResultAug 5, 2026, 04:15 PM
Zimmer Biomet Q2 Net Sales $2.18B, Net Earnings $198.3M
AI Summary
Zimmer Biomet Holdings, Inc. reported strong financial results for the second quarter of 2026, with net sales increasing by 4.8% to $2.18 billion and net earnings rising by 29.8% to $198.3 million. Diluted EPS also saw a significant jump of 33.8% to $1.03. The company continued to integrate its recent acquisitions of Paragon 28 and Monogram Technologies Inc., which are expected to enhance market share and technological capabilities. Additionally, the company is progressing with its 2025 Restructuring Plan, aiming for cost reductions and operational transformation.
Key Highlights
- Net Sales for Q2 2026 were $2,177.0M, a 4.8% increase from $2,077.3M in Q2 2025.
- Net Earnings for Q2 2026 were $198.3M, a 29.8% increase from $152.8M in Q2 2025.
- Diluted Earnings Per Share for Q2 2026 were $1.03, up 33.8% from $0.77 in Q2 2025.
- Net cash provided by operating activities for the six months ended June 30, 2026, was $807.2M.
- The 2025 Restructuring Plan is expected to result in total pre-tax charges of approximately $155M by the end of 2027.
- Acquisition of Paragon 28 in April 2025 for $1,241.5M initial consideration to expand foot and ankle segment.
- Acquisition of Monogram Technologies Inc. in October 2025 for $175.9M initial consideration for orthopedic robotics.
- Total Assets as of June 30, 2026, stood at $22,797.8M.
Price Impact
More from ZBH